pt-112

Small moleculeexperimental

Clinical trial activity

7 trials · 11 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
5
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2014 (NCT02266745)

Timeline

2010s

  1. Jan 1, 2014

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • pt-112
  • pt-112

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05104736Phase 2Dec 7, 2021National Cancer Institute (NCI)
NCT05357196Phase 1/Phase 2 (Phase 2)Apr 13, 2020Fudan University, SciClone Pharmaceuticals
NCT03409458Phase 1/Phase 2 (Phase 2)Apr 24, 2018Merck Serono, Pfizer, Phosplatin Therapeutics, University of Texas at Houston
NCT03439761Phase 1/Phase 2 (Phase 2)Mar 7, 2018Huazhong University of Science and Technology, SciClone Pharmaceuticals
NCT03288480Phase 1Dec 15, 2017Mayo Clinic, Phosplatin Therapeutics
NCT02884479Phase 1/Phase 2 (Phase 2)Aug 1, 2016National Cheng Kung University, Parexel, SciClone Pharmaceuticals
NCT02266745Phase 1Jul 1, 2014Phosplatin Therapeutics, University of Texas at Houston
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (11)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Phosplatin TherapeuticsFor profit3322014
SciClone PharmaceuticalsFor profit3312016
University of Texas at HoustonAcademic/Hospital2022014
Fudan UniversityAcademic/Hospital1012020
Huazhong University of Science and TechnologyAcademic/Hospital1012018
Mayo ClinicAcademic/Hospital1012017
Merck SeronoFor profit1012018
National Cancer Institute (NCI)Government1112021
National Cheng Kung UniversityAcademic/Hospital1012016
ParexelFor profit1012016
PfizerFor profit1012018
11 organizations
Page 1 / 1